Traditional anti-cancer therapies (surgery, radiotherapy and chemotherapy) have limited effectiveness in curbing progression
of advanced tumors. However, with advances in immunology and molecular biology in the last two decades, the prognosis of cancer
immunotherapy has improved. An emerging therapy is the cancer vaccine as adjunctive therapy. The purpose of this paper is to review
this therapeutic modality for non-small cell lung cancer.
Keywords: Immunotherapy, MAGE-A3, MUC1, non-small cell lung cancer, tumor antigens, vaccine.
Rights & PermissionsPrintExport